SynthesisTherapeutic innovation & regulatory science2022
A Systematic Review of Pharmacovigilance Systems in Developing Countries Using the WHO Pharmacovigilance Indicators.
Synthesis in Therapeutic innovation & regulatory science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Artificial intelligence and computational methods in the Asia-Pacific pharmacovigilance landscape: a systematic review.International journal of public health · 2026Pooled it
- Benchmarking Drug Regulatory Systems for Capacity Building: An Integrative Review of Tools, Practice, and Recommendations.International journal of health policy and management · 2023Pooled it
- Article
- From Product-Quality Complaints to Patient-Safety Triage: A Structured Narrative Review and Proposed PRCS-TRACE Framework.Healthcare (Basel, Switzerland) · 2026Review
- Signal Detection Using Change Point Analysis to Identify Safety Signals from Spontaneous Reports in Aortic Stent Grafts in Japan.Journal of medical systems · 2026Article
- Trends and Patterns of Adverse Drug Reaction Reporting in Sierra Leone: A Retrospective Analysis of VigiFlow Data (2008-2022).Pharmacoepidemiology and drug safety · 2026Article
- Class-level drug safety surveillance in hospital practice: A pharmacovigilance analysis of 84 therapeutic subclasses from a South Asian tertiary care center.Exploratory research in clinical and social pharmacy · 2026Article
- Regulatory and HTA framework for herbal medicines in Indonesia.Journal of pharmaceutical policy and practice · 2026Review
- Transitioning regulatory authorities in South Africa: a comparative review of the organisational structure and management practices.Journal of pharmaceutical policy and practice · 2026Review
- Medication-related nephrotic syndrome: a real-world study from 2004 to 2024 based on the Food and Drug Administration Adverse Event Reporting System.Therapeutic advances in drug safety · 2026Article
- Framework for identifying reference countries in drug safety evaluation: an application of the analytic hierarchy process.Journal of pharmaceutical policy and practice · 2026Article
- Cytopenias as Adverse Drug Reactions: A 10-Year Analysis of Reporting Structure, Rate, and Trend.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Understanding Underreporting of Adverse Drug Reactions in the Philippines: A Mixed Methods Study.Drugs - real world outcomes · 2025Article
- Assessment of knowledge and perceptions of pharmacy students toward pharmacovigilance activities, and their predictors: a cross-sectional study in Palestine.BMC medical education · 2025Article
- Assessment of Pharmacovigilance Across University Hospitals in Morocco.Drug safety · 2025Article
- Probing the in-depth analysis of Serious Adverse Drug Reactions in a tertiary care hospital of Central India.Exploratory research in clinical and social pharmacy · 2025Article
- Mycetoma managment: Therapeutic challenges and the role of pharmacovigilance.PLoS neglected tropical diseases · 2025Review
- Global pharmacovigilance reporting of the first monoclonal antibody for canine osteoarthritis: a case study with bedinvetmab (Librela™).Frontiers in veterinary science · 2025Article
- Pharmacovigilance processes in low- and middle-income countries: moving from data collection to data analysis and interpretation.Therapeutic advances in drug safety · 2025Article
- Pharmacovigilance systems for safety monitoring of herbal medicines: assessment of the national regulatory authority, manufacturers and marketing authorisation holders in Tanzania.Journal of pharmaceutical policy and practice · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the context of the growth of pharmacovigilance (PV) among developing countries, this systematic review aims to synthesise current research evaluating developing countries' PV systems' performance.
methodsEMBASE, MEDLINE, CINAHL Plus and Web of Science were searched for peer-reviewed studies published in English between 2012 and 2021. Reference lists of included studies were screened. Included studies were quality assessed using Hawker et al.'s nine-item checklist; data were extracted using the WHO PV indicators checklist. Scores were assigned to each group of indicators and used to compare countries' PV performance.
resultsTwenty-one unique studies from 51 countries were included. Of a total possible quality score of 36, most studies were rated medium (n = 7 studies) or high (n = 14 studies). Studies obtained an average score of 17.2 out of a possible 63 of the WHO PV indicators. PV system performance in all 51 countries was low (14.86/63; range: 0-26). Higher average scores were obtained in the 'Core' (9.27/27) compared to 'Complementary' (5.59/36) indicators. Overall performance for 'Process' and 'Outcome' indicators was lower than that of 'Structural'.
conclusionThis first systematic review of studies evaluating PV performance in developing countries provides an in-depth understanding of factors affecting PV system performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.